Johnson & Johnson

JNJ-N

NYSE:JNJ

147.55
0.85 (0.57%)
Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
More at Wikipedia

Analysis and Opinions about JNJ-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
August 22, 2019
There is a ruling on Monday. This is a great reason not to buy it. Some people think you should not sell it even if you would not buy it if you held it. He would stay clear of it. There is one law suit after another.
Show full opinionHide full opinion
There is a ruling on Monday. This is a great reason not to buy it. Some people think you should not sell it even if you would not buy it if you held it. He would stay clear of it. There is one law suit after another.
BUY
BUY
August 21, 2019
Really a healthcare conglomerate that has medtech and health devices. They also have medical and household products. They are currently trading at a lower multiple, due to the sector being under pressure from legislation. They also have the baby powder lawsuit, which shouldn't be too much of a problem, but the stock price takes a hit when news comes out.
Show full opinionHide full opinion
Really a healthcare conglomerate that has medtech and health devices. They also have medical and household products. They are currently trading at a lower multiple, due to the sector being under pressure from legislation. They also have the baby powder lawsuit, which shouldn't be too much of a problem, but the stock price takes a hit when news comes out.
DON'T BUY
DON'T BUY
August 13, 2019

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

Show full opinionHide full opinion

The PFE-N non-patent drugs will be dilutive for earnings in the short term. She prefers either JNJ-N or ABT-N

TOP PICK
TOP PICK
July 29, 2019
He loves the healthcare space. His model price is over $179. Yield 2.85%
Show full opinionHide full opinion
He loves the healthcare space. His model price is over $179. Yield 2.85%
PAST TOP PICK
PAST TOP PICK
July 10, 2019
(A Top Pick Jul 10/18, Up 14%) They had a lot of issues in the last year. Their phrama division is about half of their revenues and is doing quite well. This division has the highest margins. They have increased the dividend for 56 consecutive years. She would not jump in right now; buy on a pull-back.
Show full opinionHide full opinion
(A Top Pick Jul 10/18, Up 14%) They had a lot of issues in the last year. Their phrama division is about half of their revenues and is doing quite well. This division has the highest margins. They have increased the dividend for 56 consecutive years. She would not jump in right now; buy on a pull-back.
COMMENT
COMMENT
June 5, 2019
Lawsuit impacts? It is facing a lawsuit on talcum powder impact on babies. These type of lawsuits can be dragged out and become an uphill battle for the company. Since this does not represent a major portion of the revenues, it should not be a long term influence. The risk is the market will redetermine the correct trading multiple and that is hard to predict. He would rather trade a medical device ETF, that includes JNJ-N.
Show full opinionHide full opinion
Lawsuit impacts? It is facing a lawsuit on talcum powder impact on babies. These type of lawsuits can be dragged out and become an uphill battle for the company. Since this does not represent a major portion of the revenues, it should not be a long term influence. The risk is the market will redetermine the correct trading multiple and that is hard to predict. He would rather trade a medical device ETF, that includes JNJ-N.
BUY WEAKNESS
BUY WEAKNESS
June 4, 2019
They are a one stop shop in the consumer staple space with good demographic support. He expects dividend growth to continue. The negative is on the political side, which might hurt the healthcare space. He would definitely buy on weakness.
Show full opinionHide full opinion
They are a one stop shop in the consumer staple space with good demographic support. He expects dividend growth to continue. The negative is on the political side, which might hurt the healthcare space. He would definitely buy on weakness.
TOP PICK
TOP PICK
May 22, 2019
Just bought it Friday. A healthcare stock under pressure from law suites associated to its talcum products. A great company to own long term. Yield 2.7% (Analysts’ price target is $148.47)
Show full opinionHide full opinion
Just bought it Friday. A healthcare stock under pressure from law suites associated to its talcum products. A great company to own long term. Yield 2.7% (Analysts’ price target is $148.47)
BUY WEAKNESS
BUY WEAKNESS
May 14, 2019
Buy on a pullback, not now. Their pharma division is doing very well with products in the pipeline and wide margins. A strong balance sheet. Their dividend is almost 3% with a long history of increasing. A diversified, global name. This is quite defensive and good to hold in a weak economy. Lawsuits remain an overhang; JNJ has likely put aside some contingency money for these suits.
Show full opinionHide full opinion
Buy on a pullback, not now. Their pharma division is doing very well with products in the pipeline and wide margins. A strong balance sheet. Their dividend is almost 3% with a long history of increasing. A diversified, global name. This is quite defensive and good to hold in a weak economy. Lawsuits remain an overhang; JNJ has likely put aside some contingency money for these suits.
WAIT
WAIT
March 26, 2019
Always worried about large US potential lawsuits. Suffering like all the other pharma companies. Devices and consumer brands are keeping it going. Stock is not cheap. Wait for a better entry price. Lawsuits are an overhang. (Analysts’ price target is $145.00)
Show full opinionHide full opinion
Always worried about large US potential lawsuits. Suffering like all the other pharma companies. Devices and consumer brands are keeping it going. Stock is not cheap. Wait for a better entry price. Lawsuits are an overhang. (Analysts’ price target is $145.00)
BUY
BUY
February 12, 2019
It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
February 12, 2019
It's in a great space now, healthcare, given demographics and technology. The lawsuit will linger for a long time, but it's not hugely material. JNJ is a healthcare conglomrerate with consumer, medical devices and pharma divisions. It's like an ETF. A fine healthcare stock. A long-term hold if you can weather volatility surrounding the lawsuit.
HOLD
HOLD
February 8, 2019
When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
February 8, 2019
When to exit? He thinks you "go to war" with this stock. He sees 18% upside still for it. He would continue to hold it long term. He might trim some length if it makes a new high.
DON'T BUY
DON'T BUY
February 6, 2019
He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
February 6, 2019
He likes it, but wouldn't buy it. Consumer, pharma and devices are their three divisions. Only the consumer division is a problem; it has a baby powder cancer issue which is tainting the overall brand. Another headwind is branding: brands aren't any better than generics, as consumers now realize.
COMMENT
COMMENT
January 25, 2019
Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 25, 2019
Trading at 15x earnings after a pullback. It's a complicated company with so many products and now has this talcum powder issue. You won't go too wrong owning this, but will this be a compounder? He doesn't know. It's probably undervalued because of the talcum-cancer scare; markets *always* overreact to bad news. Always.
BUY
BUY
January 22, 2019
They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.
Show full opinionHide full opinion
Johnson & Johnson (JNJ-N)
January 22, 2019
They just reported solid earnings, though the stock was down today a bit. Has a wide product range sold in 200 countries. Solid and diversified. They raise their dividend every year and it rise again.
Showing 31 to 45 of 450 entries